A study from Robert et al. indicated that OAS1 expression was correlated with azacytidine (AZA) sensitivity in the NCI-60 tumor cell lines and was a biomarker for predicting AZA sensitivity of tumor cells (Banerjee et al., 2019). The gene discussed is OAS1; the disease is neoplasm.